Pharmackinetics/pharmacodynamics of ceftazidime-avibactam in adult critically ill patients receiving continuous renal replacement therapy
Data files
Nov 28, 2025 version files 10.61 KB
-
Avibactam_concentration.csv
1.71 KB
-
Ceftazidime_concentration.csv
1.71 KB
-
CRRT_parameters_data.csv
370 B
-
Demographic_data.csv
1.45 KB
-
Medication_Information.csv
892 B
-
Microbial_data.csv
874 B
-
README.md
3.61 KB
Abstract
Ceftazidime-avibactam (CAZ-AVI), a novel antibiotic, is effective in treating infections caused by carbapenem-resistant Gram-negative bacteria. However, in patients receiving continuous renal replacement therapy (CRRT), both the pharmacokinetics(PK) and pharmacodynamics(PD) of the drugs can be significantly altered. Currently, there remains a lack of clear guidelines regarding optimal dosing regimens for CAZ-AVI during CRRT. Prospectively, this study evaluated the PK/PD of CAZ-AVI in 21 critically ill patients receiving CRRT. We collected blood samples at 5-7 sampling points within one administration cycle, and then determined the total plasma drug concentrations. Phoenix was used to calculate the PK parameters. The clearance at steady-state (CLss) of patients receiving CRRT was significantly reduced, and drug exposure was also significantly increased compared to healthy subjects. Notably, four patients demonstrated the free minimum plasma concentrations (fCmin) of CAZ exceeding eight times the minimum inhibitory concentration, and 90.48% (19 cases) of the patients exhibited CAZ plasma concentrations exceeding the neurotoxicity threshold of 104 mg/L. PK/PD analysis indicated that the standard dosing regimen of 2.5 g every 8 hours of CAZ-AVI may pose a risk of excessive drug exposure. In addition, CRRT was the primary elimination pathway for CAZ-AVI in critically ill patients with acute kidney injury receiving CRRT. Significant differences in extracorporeal clearance were observed between continuous venovenous hemodialysis (CVVHD) and continuous venovenous hemofiltration (CVVH) for both CAZ and AVI; CVVH demonstrated higher clearance for CAZ and AVI compared to CVVHD. To prevent potential toxic reactions, it is urgent to establish a safer and more rational dosing regimen for patients receiving CRRT.
Dataset DOI: 10.5061/dryad.fxpnvx16s
Description of the data and file structure
This dataset contains prospective pharmacokinetic and clinical data from 21 critically ill patients receiving ceftazidime-avibactam antibiotic therapy while undergoing continuous renal replacement therapy (CRRT). The study aimed to characterize drug exposure and clearance patterns to inform optimal dosing strategies in this complex patient population. Data include serial drug concentration measurements, CRRT parameters, microbial susceptibility testing, treatment outcomes, and patient characteristics.
Files and variables
File: Demographic_data.csv
Description: Demographic and clinical characteristics of study participants
Variables
- subjectID: anonymized subject identifier
- age_year: Age category (3 categories)
- sex: Sex code (numeric coding)
- weight_kg: Body weight category (4 categories)
- clinical diagnosis: Primary diagnosis
- ALT_U/L: Alanine aminotransferase (U/L)
- AST_U/L: Aspartate aminotransferase (U/L)
- HCT: Hematocrit
- ALB_g/L: Albumin (g/L)
- SCr_umol/L: Serum creatinine (μmol/L)
- apache score: APACHE II score
- SOFA score: SOFA score
- 24-hour Urine Volume_mL: 24-hour urine output(mL)
File: CRRT_parameters_data.csv
Variables
- subjectID
- CRRT modality
- Ultrafiltration rate_mL/h
- total effluent flow rate_mL/kg/h
- The consecutive days of CRRT treatment_day
File: Ceftazidime_concentration.csv
Description: Ceftazidime plasma concentration measurements
Variables
- subjectID: Subject identifier
- Time_h: Time after dose (hours)
- Ceftazidime concentration pre-filter_mg/L: Pre-filter concentration(mg/L)
- Ceftazidime concentration post-filter_mg/L: Post-filter concentration(mg/L)
File: Avibactam_concentration.csv
Description: Avibactam plasma concentration measurements
Variables
- subjectID: Subject identifier
- Time_h: Time after dose (hours)
- Avibactam concentration pre-filter_mg/L: Pre-filter concentration(mg/L)
- Avibactam concentration post-filter_mg/L: Post-filter concentration(mg/L)
File: Medication_Information.csv
Description: Drug administration details
Variables
- subjectID: Subject identifier
- CAZ/AVI dose_g: Ceftazidime-avibactam dose(g)
- Dosage interval_h: Dosing interval(h)
- Consecutive days of medication_day: Treatment duration category
- method of administration: Route of administration
- Infusion duration_h: Infusion duration category
File: Microbial_data.csv
Description: Microbiological and treatment outcome data
Variables
- subjectID: Subject identifier
- Infections site: Infection site
- Pathogenic microorganisms: Identified pathogens
- KB value: Kirby-Bauer test results
- Susceptibility: Antimicrobial susceptibility
- Pathogen clearance: Pathogen clearance outcome
- Clinical outcome: Clinical treatment outcome
Code/software
All can be opened in Excel.
Access information
Other publicly accessible locations of the data:
- none
Data was derived from the following sources:
- none
Human subjects data
I confirm that we received explicit consent from our participants to publish the de-identified data in the public domain. We did not disclose the personal privacy of the subjects, such as names and ID numbers. Instead, we used anonymized subject numbers to represent different individual patients.